Evidence map›Paper›PMID 39554121›Full record

ArticlebioRxiv : the preprint server for biology2024

Antigen-specific T cell immunotherapy by in vivo mRNA delivery.

Fang-Yi Su, Jamison C Siebart, Ching S Chan, Matthew Y Wang, Xinyi Yao, Aaron Silva Trenkle, Avanti Sivakumar, Melanie Su, Rustin Harandi, Neha Shahrawat and 5 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Fang-Yi SuThe Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology & Emory University, Atlanta, GA 30332, USA.ORCID 0000-0003-2852-161X
Jamison C SiebartThe Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology & Emory University, Atlanta, GA 30332, USA.ORCID 0000-0002-0424-7487
Ching S ChanThe Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology & Emory University, Atlanta, GA 30332, USA.
Matthew Y WangThe Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology & Emory University, Atlanta, GA 30332, USA.
Xinyi YaoThe Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology & Emory University, Atlanta, GA 30332, USA.
Aaron Silva TrenkleThe Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology & Emory University, Atlanta, GA 30332, USA.
Avanti SivakumarThe Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology & Emory University, Atlanta, GA 30332, USA.
Melanie SuThe Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology & Emory University, Atlanta, GA 30332, USA.
Rustin HarandiThe Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology & Emory University, Atlanta, GA 30332, USA.
Neha ShahrawatThe Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology & Emory University, Atlanta, GA 30332, USA.
Chi H NguyenThe Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology & Emory University, Atlanta, GA 30332, USA.
Anshika GoenkaWinship Cancer Institute of Emory University, Atlanta, GA 30322, USA.
Jinhee MunThe Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology & Emory University, Atlanta, GA 30332, USA.
Madhav V DhodapkarWinship Cancer Institute of Emory University, Atlanta, GA 30322, USA.
Gabriel A KwongThe Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology & Emory University, Atlanta, GA 30332, USA.ORCID 0000-0002-6255-6755

Funding

Research Training Program Plan on Cell and Tissue Engineering (CTEng)T32GM008433 · NIGMS · GEORGIA INSTITUTE OF TECHNOLOGY · PI GARCIA, ANDRES J · 1991 to 2021
$7.1M
Bioinspired nanovectors for CRISPR/Cas9-mediated CAR T cell manufacturingR21CA260247 · NCI · GEORGIA INSTITUTE OF TECHNOLOGY · PI KWONG, GABRIEL A · 2022 to 2023
$403k
Democratizing CAR T cell therapy by in situ programming of virus-specific T cellsK99CA276890 · NCI · GEORGIA INSTITUTE OF TECHNOLOGY · PI SU, FANG-YI · 2023 to 2024
$222k
NCI NIH HHS K99 CA276890NCI NIH HHS R21 CA260247NIGMS NIH HHS T32 GM008433
6 · The paper itself

Abstract

Immunotherapy has shown promise for treating patients with autoimmune diseases or cancer, yet treatment is associated with adverse effects associated with global activation or suppression of T cell immunity. Here, we developed antigen-presenting nanoparticles (APNs) to selectively engineer disease antigen (Ag)-specific T cells by

Identifiers

PMID39554121
PMCPMC11566043

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.